| Title |
Autoantibody development under treatment with immune checkpoint inhibitors
|
|---|---|
| Published in |
Cancer Immunology Research, January 2019
|
| DOI | 10.1158/2326-6066.cir-18-0245 |
| Pubmed ID | |
| Authors |
Emma C de Moel, Elisa A Rozeman, Ellen H Kapiteijn, Els M E Verdegaal, Annette Grummels, Jaap A Bakker, Tom W J Huizinga, John B Haanen, René E M Toes, Diane van der Woude |
X Demographics
The data shown below were collected from the profiles of 19 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 8 | 42% |
| Singapore | 2 | 11% |
| Venezuela, Bolivarian Republic of | 1 | 5% |
| Australia | 1 | 5% |
| India | 1 | 5% |
| United Kingdom | 1 | 5% |
| Germany | 1 | 5% |
| Unknown | 4 | 21% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 10 | 53% |
| Members of the public | 8 | 42% |
| Practitioners (doctors, other healthcare professionals) | 1 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 100 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 100 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 20 | 20% |
| Student > Ph. D. Student | 12 | 12% |
| Student > Master | 9 | 9% |
| Student > Doctoral Student | 9 | 9% |
| Other | 7 | 7% |
| Other | 17 | 17% |
| Unknown | 26 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 38 | 38% |
| Immunology and Microbiology | 12 | 12% |
| Biochemistry, Genetics and Molecular Biology | 10 | 10% |
| Agricultural and Biological Sciences | 2 | 2% |
| Computer Science | 2 | 2% |
| Other | 3 | 3% |
| Unknown | 33 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 November 2021.
All research outputs
#1,924,584
of 25,559,053 outputs
Outputs from Cancer Immunology Research
#199
of 1,572 outputs
Outputs of similar age
#43,466
of 447,458 outputs
Outputs of similar age from Cancer Immunology Research
#7
of 79 outputs
Altmetric has tracked 25,559,053 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,572 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.0. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 447,458 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 79 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.